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a b s t r a c t
Outbreaks of Rift Valley fever in Kenya, Madagascar, Mauritania, and South Africa had devastating effects
on livestock and human health. In addition, this disease is a food security issue for endemic countries.
There is growing concern for the potential introduction of RVF into non-endemic countries. A number
of single-gene target ampliﬁcation assays have been developed for the rapid detection of RVF viral RNA.
This paper describes the development of an improved ampliﬁcation assay that includes two conﬁrmatory
target RNA segments (L and M) and a third target gene, NSs, which is deleted in the Clone 13 commer-
cial vaccine and other candidate vaccines. The assay also contains an exogenous RNA control added
during the PCR setup for detection of ampliﬁcation inhibitors. The assay was evaluated initially with
samples from experimentally infected animals, after which clinical veterinary and human samples fromeal-time RT-PCR endemic countries were tested for further evaluation. The assay has a sensitivity range of 66.7–100% and
a speciﬁcity of 92.0–100% depending on the comparison. The assay has an overall sensitivity of 92.5%,
speciﬁcity of 95% and a positive predictive value of 98.7%. The single-tube assay provides conﬁrmation
of the presence of RVFV RNA for improved conﬁdence in diagnostic results and a “differentiate infected
from vaccinated animals” (DIVA) – compatible marker for RVFV NSs – deleted vaccines, which is useful
s, bufor RVF endemic countrie
. Introduction
Recent outbreaks of Rift Valley fever (RVF) in Kenya (Nguku
t al., 2010), Madagascar (Carroll et al., 2011), South Africa (Archer
t al., 2011) and Mauritania (El Mamy et al., 2011) have high-
ighted the need for rapid and reliable diagnostic tools for detecting
his zoonotic disease of signiﬁcant public health, veterinary and
ocio-economic importance. Rift Valley fever virus (RVFV), a
osquito-borne Bunyavirus, is enzootic in sub-Saharan Africawith
VFVepidemics occurring at irregular intervals primarily in eastern
nd southern Africa (Gerdes, 2002). There are agricultural and pub-
ic health concerns for the potential intentional or unintentional
∗ Corresponding author. Tel.: +1 785 537 5570; fax: +1 785 537 5560.
E-mail address: William.wilson@ars.usda.gov (W.C. Wilson).
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Open access under CC BY license.t especially important in non-endemic countries.
Published by Elsevier B.V.
introduction of RVFV into non-endemic countries (Borio et al.,
2002; Sidwell et al., 1994; Weaver and Reisen, 2010). The ability
of arboviruses to rapidly establish themselves in new ecosystems
was exempliﬁed by the introduction of West Nile virus to North
America (Roehrig et al., 2002). Disease outbreaks vary signiﬁcantly
in the percentage of susceptible animals affected, ranging from15%
to 90% (EMPRES, 2005). Those which succumb display severe dis-
ease, coupled with abortion in pregnant cattle, sheep, and goats
and 70–100% mortality in young animals (Gerdes, 2004). Endemic
prevalence of antibody in humans ranges from 5 to 40% (EMPRES,
2005), but increases with risk factors such as livestock handling,
exposure to aerosols during the slaughter of infected animals and
consumption of raw milk (Gerdes, 2004). Infection of humans can
result in hepatitis, hemorrhagic fever, encephalitis, ocular degener-
Open access under CC BY license.ation, and death (Al-Hazmi et al., 2003; Archer et al., 2011; Gerdes,
2004).
Although veterinary vaccines are available, immunization
of humans can only be accomplished through the use of an
ologic
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xperimental inactivated RVFV vaccine with limited availability
Rusnak et al., 2011). Veterinary vaccines used in endemic and
pidemic countries include a formalin-inactivated vaccine and an
ttenuated vaccine strain (Smithburne neurotropic strain) thatwas
eveloped in 1949 (Gerdes, 2002; Smithburn, 1949). A naturally
ttenuated strain isolated from an asymptomatic human case in
he Central African Republic, Clone 13, which has a large deletion
n the open reading frame of the NSs protein, has been demon-
trated to be safer than the Smithburn attenuated vaccine strain,
hich can cause abortions (Dungu et al., 2010; von Teichman et al.,
011). Clone13 is nowcommercially available for use in livestock in
outhAfrica. Other attenuated vaccine candidates have been inves-
igated and preliminary results are promising, but these candidates
re not yet licensed for human or animal use (Bird et al., 2008;
orrill and Peters, 2011) (for a recent review refer to Ikegami and
akino (2009)). An important feature of these newer veterinary
accines is the ability to differentiate infected from vaccinated ani-
als (DIVA). To employ aDIVA control strategy effectively, relevant
ompanion diagnostic assays are required.
The RVFV genome consists of three negative sense, single-
tranded RNA segments encoding structural and non-structural
roteins. The large segment (L) encodes the RNA-dependent
NA polymerase which associates with the nucleocapsid protein
encoded by the small (S) segment) and genome segments to form
ibonucleocapsids. The S-segment, which utilizes an ambisense
oding strategy, additionally encodes a non-structural protein
NSs), which is the virulence factor of the virus that counteracts the
ost innate immune response. The medium (M) segment encodes
wo major envelope glycoproteins and two minor proteins, one of
hich is non-structural and may have anti-apoptotic properties
Won et al., 2006).
Diagnostic assays for detection of RVFV antibodies and anti-
en have been developed. Various enzyme-linked immunosorbent
ssays (ELISAs) have been developed for the detection of antibodies
oRVFV inhumans, sheep, cattle andwildlife species (Meegan et al.,
987; Paweska et al., 2005a,b, 2008; Williams et al., 2011). Anti-
en capture ELISAs are also available (Fukushi et al., 2012; Morvan
t al., 1991; Jansen van Vuren and Paweska, 2009). Rapid RVFV
NA detection methods using real-time reverse transcriptase-
olymerase chain reaction (rRT-PCR) have also been reported (Bird
t al., 2007a; Drosten et al., 2002; Garcia et al., 2001). In addition, a
eal-time reverse transcription loop-mediated isothermal ampliﬁ-
ation (LAMP) test for rapid detection of RVFV has been developed
Euler et al., 2012; Le Roux et al., 2009; Peyreﬁtte et al., 2008).
ecently,methods for rapid inactivationof thevirus and single-step
RT-PCR for detection of RVFV RNA were developed (Drolet et al.,
012). None of these tests are compatible or applied as a DIVA com-
anion diagnostic assay. Furthermore, the need for detection of an
ntroduced foreign animal pathogen is substantiated by its signif-
cant economic impact. Therefore, in this study a robust one-step
uadruplex rRT-PCRassaywasdeveloped thatallows forDIVAcom-
atibility, detection conﬁrmation, and exogenous internal control
mpliﬁcation.
. Materials and methods
.1. Viruses
RVFV MP-12 was propagated in fetal lung ﬁbroblast (MRC-5)
ell cultures. Propagation of RVFV strains from varying geograph-
cal and locations over 63 years was done in conﬂuent African
reen monkey kidney epithelial cells (Vero). Cells were infected
sing 0.01 multiplicity of infection and RNA extractions were per-
ormed when approximately 80–95% of the infected cells showed
ytopathology.al Methods 193 (2014) 426–431 427
2.2. RNA extraction from infected cells or serum
Total RNA was extracted from cells using a variety of RNA
isolation kits as per the manufacturer’s protocols. The choice of
extraction kit was based on local availability and/or preferences.
RNA from RVFV propagated in cell culture was isolated using Trizol
LS according to the manufacturer’s recommendations (Life Tech-
nologies, Inc., Grand Island, NY). The primary method used for
serum or tissue samples was the high-throughput RNA extrac-
tion method using the magnetic-bead capture kits: MagMAX-96
total RNA Isolation andMagMAXViral RNA Isolation. Brieﬂy, 130l
of lysis/binding buffer was added to 50l of sample and mixed
by shaking in a 96-well plate. Bead mix (20l) was then added
and the mixture was shaken for 5min. Four subsequent washes
were performed (150l each) and the RNA was eluted in 50l
of elution buffer at 65 ◦C. RNA was extracted both manually and
automatically using available commercial kits in use at the vari-
ous cooperating laboratories. The primary kit used in development
of the assay was the Applied Biosystems MagMax Express system
(Life Technologies, Inc., Grand Island, NY). RNA was quantitated
using UV spectroscopy. RNA from veterinary clinical samples was
puriﬁed using the MagNA Pure High Performance Total Nucleic
Acid Isolation Kit together with the MagNA Pure LC according
to manufacturers speciﬁcations (Roche Applied Science, South
Africa).
2.3. Primer/probe design
The initial primer and probe design was based on previous real-
time assays (Bird et al., 2007a; Drosten et al., 2002; Garcia et al.,
2001). Subsequent new primer and probes were designed using
Visual OMP (DNA Software, Ann Arbor, MI). The RVFV vaccine
strain,MP-12,wasused as amodel virus formanyof the studies due
to lack of local access to an approved BSL-3+ laboratory for virulent
RVFV. The L segment primer designwasmodiﬁedwhenMP-12was
used to account for sequence variation. The two exogenous inter-
nal control RNA primer and probe combinations were based on
previously published assays (Drolet et al., 2012; Schroeder et al.,
2012). The ﬁnal primer design contained 4 primer sets and probes
(Tables 1 and 2).
2.4. Optimization of new RVFV signatures for real-time RT-PCR
(rRT-PCR)
The rRT-PCR procedure was performed as described previ-
ously (Wilson et al., 2009a,b). Optimization of the primer and
probes were conducted individually, followed by multiplexing.
Various quenchers and ﬂuorescent dyes were evaluated using
limit of detection (LOD) studies on the instruments available.
The primary instrument used for a small number of samples
was the Cepheid SmartCycler II (Cepheid Inc., Sunnyvale, CA),
while for high-throughput the Agilent MX3005p (Agilent Tech-
nologies, Inc., Santa Clara, CA) was used. The initial evaluation of
the primer probe designs was done using various plasmids con-
taining RVFV target L, M and S sequences. For LOD experiments,
samples were run in triplicate with viral RNA puriﬁed from 10-
fold dilutions of RVFV MP-12 titered stock or in duplicate from
a virulent RVFV titered stock. In some cases plasmids containing
the target virulent RVFV sequences were used to facilitate opti-
mization. Ct values were recorded and the mean and standard
deviations calculated. Initial experiments were conducted with
only the RVFV signatures and optimized using the iCycler (Bio-
Rad, Hercules, CA). Two external RNA ampliﬁcation controls were
later added, optimized and evaluated on the Cepheid SmartCycler
II.
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Table 1
RVFV primers for real time RT-PCR.
Primer Orient Final conc. (M) Tm (◦C) Nucleotide sequence 5′–3′
RVFL-2912fwdGGa Forward 10 53.1 TGA-AAA-TTC-CTG-AGA-CAC-ATG-G
RVFL-2981revAC Reverse 10 52.7 ACT-TCC-TTG-CAT-CAT-CTG-ATG
RVFV-M(G2)-F(RVAs) Forward 10 56.2 CAC-TTC-TTA-CTA-CCA-TGT-CCT-CCA-AT
RVFV-M(G2)-R (RVS) Reverse 10 56.3 AAA-GGA-ACA-ATG-GAC-TCT-GGT-CA
RVFV-S(NSs)-F Forward 20 55.7 TGA-TGG-TCC-TCC-CAG-GAT-AC
RVFV-S(NSs)-R Reverse 20 55.8 ACT-AGG-ACG-ATG-GTG-CAT-GA
RVF-MP12-3296Fb Forward 10 53.6 CCT-CAC-TAT-TAC-ACA-CCA-TTC
RVF-MP12-3453Rb Reverse 10 50.5 ATC-ATC-AGC-TGG-GAA-GCT
a RVF L segment primers and probes identical to Bird et al. (2007a,b). RVF M primers and probes identical to Drosten et al. (2002).
b RVF-MP12 primers substituted for RVFL primers when RNA from RVFV MP-12 vaccine strain was used.
Table 2
RVFV probes for real time RT-PCR.
Probe Fluorescent reporter dye (5′ end) Quencher (3′ end) Final conc. (M) Tm (◦C) Nucleotide sequence 5′–3′
RVFL-probe-2950 CAL FLUOR RED 610 BHQ2 10 62.9 CAA-TGT-AAG-GGG-CCT-GTG-TGG-ACT-TGT-G
1
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Institute for Communicable Diseases (NICD) in South Africa and
conﬁrmed by the previously validated reverse transcriptase loop-
mediated ampliﬁcation assay (RT-LAMP) (Le Roux et al., 2009), alsoRVFV-M(G2) FAM BHQ1
RVFV-S(NSs) QUASAR 670 BHQ2
RVF-MP12-3371P CAL FLUOR RED 610 BHQ2
.5. Real-time reverse transcriptase-polymerase chain reaction
rRT-PCR)
Final analysis was done after combining the RVFV triplex L, M
nd S primers and probes and one of the external RNA control com-
inations. The rRT-PCR was conducted using AgPath ID rRT-PCR
it (Life Technologies, Inc., Grand Island, NY) and cycle times of
5 ◦C for 10min, 95 ◦C for 10min, followed by 40 cycles of 95 ◦C for
0 s and 60 ◦C for 1min. Diagnostic test evaluation statistics was
alculated (MedCalc Software, Mariakerke, Belgium).
. Results
.1. Multiplex rRT-PCR development and optimization
A one-step multiplex RT-PCR was initially developed based on
revious real-time assays (Bird et al., 2007a; Drosten et al., 2002;
arcia et al., 2001). The primer-probe set targeting the S-segment
id not perform consistently in the triplex assays. To further evalu-
te thedesign, alignmentsweremadeof all full-length sequences of
he RVFV L, M and S RNA segments available from Genbank. Highly
onserved regions were then identiﬁed for use in designing the
eal-time assay. These conserved segments were exported to Visu-
lOMP and underwent further analysis for real-time development
n silico. Further optimization was conducted piecewise with L, M
nd S in vitro, with plasmids containing half- to full-length genome
egments from virulent strains of RVFV to determine feasibility for
ultiplexing.No signiﬁcant sequence interactionswere foundafter
BLAST search with the ﬁnal designed primers. Plasmid DNA was
erially diluted 6-fold and tested with various primers and probes
ndividually and then multiplexed; multiple chemical and process
arameters were evaluated during the optimization. After initial
ptimization with plasmid DNA, MP-12 total RNA was extracted
rom MRC5 cells at 80–95% CPE using Trizol LS following the man-
facturer’s protocol. This total RNA was serially diluted 6-fold
nd tested in the same fashion as for cDNA optimization. Optimal
rimer and probe set sequences can be found in Tables 1 and 2.
.2. Quadruplex assay with evaluation of an exogenous armored
nterovirus RNA controlOnce the assay was optimized using the model system it was
valuated in laboratories in RVF endemic countrieswith authoriza-
ion to work with virulent RVFV. The ﬁrst design using the triplex63.7 AAA-GCT-TTG-ATA-TCT-CTC-AGT-GCC-CCA-A
62.5 TCC-TGG-CCT-CTT-GGA-GAA-CCC-TC
62 CTG-AGA-TGA-GCA-AGA-GCC-TGG-TTT-GTG-A
for all three genome segmentswith different reporter dyes for each
segmentwas evaluated in theKenyaAgricultural Research Institute
(KARI). It was determined that the assay is able to detect Smithburn
vaccine andKenya 2007 outbreak strains of RVFV. The assay did not
cross-react with Nairobi sheep disease virus that also causes hem-
orrhagic disease in ruminants. The conditionof someof the samples
clearly indicated that an external control was needed to control for
RT-PCR inhibition. Previously, exogenous armoredenterovirusRNA
(Asuragen, Austin, TX) was successfully employed in a single-plex
rRT-PCR assay (Drolet et al., 2012); therefore, it was decided to use
the same control in this assay. The limit of detection of the quadru-
plex assay with viral RNA extracted from diluted titered stock of
RVFV South African strain AR 20368 was 0.5 TCID50/ml (Fig. 1). No
cross-reaction was found when the quadruplex assay was evalu-
ated against a panel of nine other abortogenic or hemorrhagic viral
agents (Table 3). In a separate experiment, a sample known to be
positive for Nairobi Sheep disease virus also tested negative with
the triplex real-time RT-PCR assay. The ability of the assay to detect
RVFV strains from varying geographical locations isolated over a
period spanning 63 years was evaluated (Table 4). The assay did
not consistentlydetect theS segmentwhen theexogenousarmored
enterovirus RNA control was used. To compensate for this problem
at this time the triplex assaydesign (excluding armoredenterovirus
RNA, primer andprobe)was used for further evaluation. Thirty pos-
itive and 15 negative human sera samples, tested at the NationalFig. 1. Example of limit-of-detection analysis using RNA extracted from 10-fold
dilutions of titered Rift Valley fever virus.
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Table 3
Arboviruses tested that are not detected by the RVFV quadruplexrRT-PCR assay.
Virus Family Genus Titer
(log TCID50/ml)
Akabane Bunyaviridae Orthobunyavirus 6.8
Arumowot Bunyaviridae Phlebovirus 4.8
Chikungunya Togaviridae Alphavirus 7.5
Gabek Forest Bunyaviridae Phlebovirus 7.0
Gordil Bunyaviridae Phlebovirus 5.8
Saint Floris Bunyaviridae Phlebovirus 5.8
Dengue type I Flaviviridae Flavivirus 5.5
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Table 5
Comparison of the RVFV quadruplex rRT-PCR to previously run monoplex rRT-PCR
assays on clinical veterinary samples.
1-Plex +’ve 1-Plex −’ve Totals
a.RVFviral RNApositive samples fromexperimental infectionsof sheep, goats andcalves
4-Plex +’ve 93 0 93
4-Plex −’ve 0 0 0
Totals 93 0 93
Sensitivity 100%
Speciﬁcity 100%
Positive predictive value 100%
RT-LAMP +’ve RT-LAMP −’ve Totals
b. Human clinical samples
4-Plex +’ve 30 0 30
4-Plex −’ve 0 15 15
Totals 30 15 45
Sensitivity 100%
Speciﬁcity 100%
Positive predictive value 100%
1-Plex +’ve 1-Plex −’ve Totals
c. Veterinary clinical samples
4-Plex +’ve 58 2 58
4-Plex −’ve 16 20 38
Totals 74 22 96
Sensitivity 75.7%
Speciﬁcity 90.9%
Positive predictive value 96.6%
1-Plex +’ve 1-Plex −’ve Totals
d. Total clinical samples
4-Plex +’ve 88 2 88
4-Plex–‘ve 16 35 53
Totals 104 37 141
Sensitivity 84.6%
Speciﬁcity 94.6%
T
RWest Nile (lineage 1) Flaviviridae Flavivirus 7.8
Yellow Fever Flaviviridae Flavivirus 6.0
ielded identical resultswith the triplex formatwithout anexternal
NA control (Table 5b).
.3. Quadruplex assay with exogenous internal positive control
XIPC) control evaluation
An XIPC control (Schroeder et al., 2012) was substituted for the
xogenous armored enterovirus RNA control,which providedmore
onsistent results when run against RNA from samples from RVFV
P-12 infected cell-cultures and experimentally infected calves
nd lambs. This new quadruplex assay was also run against RVFV
NAextracted from sera of 25 calf, 27 goat and 41 sheep sera exper-
mentally infected with RVFV ZH501 strain. All of these samples
hat were positive by the previously published monoplex rRT-PCR
ssay (Drolet et al., 2012) were also positive with the new quadru-
lex assay. The diagnostic speciﬁcity and analytical sensitivitywith
ample panels in Tables 3 and 4 were identical (Table 5a). The new
uadruplex assay was evaluated at the ARC-Onderstepoort Veteri-
ary Institute (SouthAfrica) to compare it to themonoplex rRT-PCR
ssay (Drosten et al., 2002) that was used for diagnosis of animal
ases during the South African 2010 RVF outbreak. The assay was
ble to differentiate RNA from RVFV vaccine strain Clone 13 RNA
rom wild-type viral RNA. The sensitivity of the assay was poor,
etecting only 78.4% of the ﬁeld strain samples evaluated with the
ssumption that the original monoplex assay was correct. Of the
4 samples detected by the monoplex assay, but negative by the
uadruplex assay, 4 had a positive detection of one segment only
ith the quadruplex assay. The samples not detected all had low
mounts of viral RNA as evidenced by late Ct values when tested
y the monoplex rRT-PCR. This low sensitivity was conﬁrmed in
ost but not all by running individual segmentmonoplex real-time
T-PCR assays. The speciﬁcity in the analysis of veterinary clinical
amples was 90.9%, resulting in an overall positive predictive value
able 4
epresentative Ct values in detection of RVFV strains from various countries over 63 year
Strain Year of isolation Source Origin
Smithburn (UGA44) 1944 Uganda
Lunyo UGA 1955 Mosquito Uganda
B1143KEN77 1977 Kenya
ZH 501 EGY77 1977 Human Egypt
ZH548 EGY77 1977 Human Egypt
VRL2230/78 1978 Bovine Zimbabwe
ArD38388BF83 1983 Mosquito Burkina Faso
ArD3861SEN83 1983 Mosquito Senegal
SPU384001KEN97 1997 Kenya
AR 21229 2000 Saudi Arabia
RVF 117/06 2006 Human Kenya
AR 52/08 2008 Human South Africa
SA 69/10 2010 Human South Africa
SA579/11 2011 South Africa
a Numbers are Ct or cycle threshold values.
b nd: not detected.Positive predictive value 97.8%
of 96.7%. The quadruplex assays with the XIPC control also indi-
cated that 14% of the samples were negative for the NSs region of
the RVFV S segment. This percentage of samples that the S target
did not amplify is likely a reﬂection of the inclusion of samples from
a recently vaccinated herd, probably with the NSs deletion Clone
13 vaccine strain.The ability of the quadruplex assay using the XIPC control to
detect the same RVFV strains and RNA extractions that was pre-
viously evaluated using the armored enterovirus RNA exogenous
RNA control was determined. Contrary to the previous external
s.
No RNA control With XIPC RNA control
L M S L M S
13.2a 14.8 18.9 12.5 12.2 12.4
13.7 12.2 12.3 17.0 15.4 17.0
12.3 12.1 12.2 12.6 12.1 12.4
12.9 12.4 13.9 14.1 13.8 13.3
13.4 12.0 13.9 16.3 13.4 14.7
12.6 12.1 12.2 12.2 12.6 12.4
17.7 17.4 16.3 12.1 12.7 12.2
12.3 12.5 12.3 12.6 12.1 12.5
12.3 12.0 13.5 12.2 12.2 13.4
12.3 12.6 12.8 12.1 12.7 12.2
23.9 17.5 ndb 12.8 12.4 12.3
12.6 12.8 12.5 12.8 13.4 12.8
14.6 14.6 15.5 14.7 15.1 15.2
12.1 12.1 12.5 12.5 12.4 12.9
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ontrol, the assay with the XIPC control did consistently detect the
-segment target. Overall, the quadruplex assay performed better
ith inclusion of the XIPC control when compared to using the
rmored enterovirus RNA control or the triplex format.
. Discussion
The possible unintentional or intentional introduction of RVFV
nto a non-endemic country is of signiﬁcant concern and it is there-
ore considered a high priority zoonotic disease (Chevalier et al.,
010; Hartley et al., 2011). Disease outbreaks begin in domestic
ivestock but often go undetected until human cases are conﬁrmed.
herefore, there is a need for diagnostic tools that rapidly and
peciﬁcally detect RVF virus in samples from infected animals. A
umber of assays are available for RVF diagnosis but many are not
eadily available in non-endemic countries (Wilson et al., 2013).
deally, for non-endemic countries these assays should be safe to
roduce, store and handle in veterinary diagnostic laboratories.
enetic ampliﬁcation assays, including real-time RT-PCR assays,
eet these desired requirements. A sample handling protocol that
uickly inactivates the potentially infected sample, yet facilitates
ucleic acid extraction, leading to a single tube rRT-PCR assay
hat includes an internal exogenous RNA ampliﬁcation control was
eveloped previously (Drolet et al., 2012). The current rRT-PCR
ssays all detect a single region on the RVF viral genome. Although
heRVFVgenome ishighly conserved (Birdet al., 2007b;Grobbelaar
t al., 2011), genetic mutation that could affect the sensitivity
f the assay always remains a possibility. The detection of RVF
n a non-endemic country could have signiﬁcant socio-economic
mplications. The assay design reported here is advantageous over
revious assays in that it detects all three RVF viral genome seg-
ents, eachwith a different reporter dye. This design thus provides
nternal conﬁrmation within a single tube assay. It is also useful
n endemic countries that are using the licensed Clone 13 vac-
ine (von Teichman et al., 2011) in that the S segment target is
ithin the deleted portion of this product. The ability to differen-
iate infected from vaccinated RVF viral RNA would have a limited
ime frame of effectiveness since the RNA persists from 2 to 6 days
ost infection or vaccination (Drolet et al., 2012). During the evalu-
tion in South Africa there was an incident where vaccination had
ccurred just prior to observation of clinical disease in a sheep
erd. In these samples this quadruplex analysis was found to be
seful because it was able to establish that vaccine was present in
ome but also wild-type RVFV was present in other samples from
his herd (data incorporated in overall evaluation). Thus wild-type
nfectionhadoccurred too soon after vaccination to prevent clinical
isease observed. The sensitivity of the assay depends signiﬁcantly
n the sample size and extraction protocol. When whole blood or
erum samples were analyzed where the amount of material was
ot limited, the quadruplex assay was of identical sensitivity to
tandard assays currently inuse. The tissue samples evaluatedwere
rom the 2010 South Africa RVF outbreak and were processed by
ne staffmemberwhowasvaccinated forRVF. To facilitate the sam-
le handling process, swabs of the tissue sample were later used in
any of the cases. In this case the amount of target RNA was more
imited. The quadruplex assaywas not as sensitive as themonoplex
ssay in detecting RNA in these samples (Drosten et al., 2002). All
f the samples scored as “not detected”, had high Ct values >30,
xcept for one with a value of >26 with the monoplex assay. These
ssays were done on frozen samples and 3 of the negative sam-
les were also negative by monoplex as the time of the evaluation.
t is not surprising that a quadruplex assay would have reduced
ensitivity, but this can likely be improved by a small increase in
he amount of extracted material used and/or improved extraction
rocesses.al Methods 193 (2014) 426–431
Two external RNA ampliﬁcation controlswere evaluated as use-
ful additions to allow for the detection of PCR inhibitors. Both the
armored enterovirus RNA (Drolet et al., 2012) and the XIPC con-
trols (Schroeder et al., 2012) worked well with a majority of the
samples and strains tested, however, the armored enterovirus RNA
deleteriously affected the detection of the S segment target for a
few strains. This may be due to run-to-run variations of the lev-
els of S target. At the time of this analysis, the RNA from these
samples was limited and further evaluation of these two external
positive controls could not be re-run. The inconsistency with the
armored enterovirus RNA was only noted in 30% of samples where
the S target was detected in the triplex format (unpublished data).
The design was limited to the NSs-encoding region of the RVF S
viral genome segment, for DIVA compatibility with NSs-deleted
attenuated vaccines. Four NSs primer sets were evaluated before
a suitable pair was found to be effective and not to interfere with
the L and M primers and probes. In future studies, the primer and
probe sets targeting the L and M segments could be redesigned to
reduce observed primer interaction, thus allow for a more consis-
tent detection of the NSs target region. However, with the XIPC
control the assay appeared to have improved speciﬁcity, detecting
all three targets for all the strains evaluated. The L and M primer
designs are from previously published procedures and are effec-
tively being used in veterinary diagnostic laboratories currently.
Therefore, to redesign the primer/probes at this time due to incon-
sistency with the enterovirus RNA control is not appropriate. The
human clinical samples were run prior to the addition of the XIPC
control. Unfortunately, these samples were no longer available to
re-run using the current design. To obtain an overall estimate of the
sensitivity using the available data, the veterinary and human data
sets were combined resulting in an overall sensitivity of 82.7% and
speciﬁcity of 94.6%. The overall evaluation of the assay was likely
affected by the use of multiple RNA puriﬁcation methods including
both manual and automated procedures.
The triplex primer and probe design for all three genome seg-
ments of RVF virus can be utilized with a variety of instrument
formats. The reporter and quenchers should be chosen according to
the speciﬁcations of the instrumentants available. In cases where
instruments do not have four-color channel capability, the L and
M probes can utilize the same reporter dye using the S target as
the conﬁrmatory reporter forwild-type RNA. The quadruplex assay
provides a more robust format with internal conﬁrmation, poten-
tial DIVA-compatible RNA marker capability and the capacity to
control for potential PCR inhibitors. An external RNA control can be
used but in the evaluations the XIPC control had better speciﬁcity
with the RVFV strains tested. Thus, the quadruplex assay is a useful
new RVF viral genome detection tool for use in both endemic and
non-endemic countries.
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